GlassScriptPhysician profile
Jeffrey A Gordon
NPI 1417966862
$2,089.50
in general payments reported to CMS, 2019-2025
24 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $68.80 · 2021: $50.49 · 2022: $161 · 2023: $476 · 2024: $626 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $298.30 | 2019-2024 | Clareon, Hydrus Microstent, Simbrinza |
| Allergan, INC. | $224.82 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $207.40 | 2019-2025 | Cequa |
| Medtronic, INC. | $194.81 | 2022-2025 | Interstim |
| Novartis Pharmaceuticals Corporation | $160.38 | 2019-2023 | |
| Abbott Laboratories | $136.39 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $116.33 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $110.83 | 2023-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $105.57 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Abbvie INC. | $72.82 | 2023-2025 | |
| Harrow Eye, LLC | $65.87 | 2024-2025 | Vevye |
| Amgen INC. | $55.64 | 2025 | Tepezza |
| Thea Pharma INC. | $50.61 | 2022-2024 | Iyuzeh |
| Mindray Ds USA, INC. | $38.70 | 2024 | A7 Anesthesia System |
| Kala Pharmaceuticals, INC. | $35.74 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $32.58 | 2024 | Oxervate |
| Glaukos Corporation | $29.17 | 2024 | Idose |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.97 | 2019 | |
| Conmed Corporation | $28.29 | 2025 | Visiclear |
| Organogenesis INC. | $25.22 | 2024 | Affinity |
| Shire North American Group INC | $24.75 | 2019 | |
| Ocular Therapeutix, INC. | $20.81 | 2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $12.91 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.